Wire · operational-macro
aTyr Pharma Announces Alignment with FDA on Phase 3 Study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
aTyr Pharma has reached agreement with the FDA on the protocol for a global Phase 3 trial of efzofitimod to treat pulmonary sarcoidosis, planning study initiation in Q4 2026. The randomized trial will evaluate efzofitimod's efficacy and safety with forced vital capacity as the primary endpoint.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 24 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
Drug developers in lung disease biotech have a clearer path to regulatory acceptance in pulmonary sarcoidosis trials. You can consider accelerating plans to engage FDA early for study design alignment to avoid delays.
◆ Coverage
2 sources · first reported 24 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics